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Abstract 
Purpose of review: 
At present, the most common diagnostic measures for the autoimmune neuromuscular 
disease myasthenia gravis (MG) are radioimmunoprecipitation assay (RIPA), enzyme-linked 
immunosorbent assay (ELISA), and cell-based assay (CBA).  Considering the pitfalls of 
these diagnostic assays, this review describes the advantages of using Xenopus tissue cultures 
for MG diagnosis and research.    
 
Recent findings: 
Our recent study described a novel CBA involving Xenopus tissue cultures for MG 
serological diagnosis.  Moreover, this CBA can potentially be applied to elucidate the 
pathogenic mechanisms underlying AChR endocytosis and degradation, and to develop and 
validate potential therapeutic strategies for MG. 
 
Summary: 
Although most CBAs are relatively labor intensive, Xenopus CBA is a promising tool 
for the initial clinical serological diagnosis and for the pathological research of MG.  The future 
studies will be devoted to gain a better understanding of the etiology of MG and to provide a 
therapeutic intervention for this disease. 
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Introduction 
The African clawed frog Xenopus is the leading vertebrate model for the study of 
gene function in embryonic development for the past 50+ years [1, 2].  Using a combination 
of various techniques, including molecular manipulation, cell lineage analysis, and live-cell 
imaging, Xenopus offers an ideal platform for studies on the molecular and cellular controls 
of patterning formation, morphogenesis and organogenesis during embryonic development.  
Remarkably, the well-established Xenopus primary cultures of nerve and muscle tissues have 
been used extensively to elucidate the cellular and molecular mechanisms of neuromuscular 
junction (NMJ) development [3, 4].  Embryonic Xenopus tissue cultures provide several 
unique advantages, including the feasibility of forming functional NMJs in vitro by co-
culturing the muscle cells and spinal neurons (Figure 1a, b), over-expression of green 
fluorescent protein (GFP) fusion proteins or their mutant, and morpholino-mediated 
knockdown of a specific endogenously expressed protein can be easily performed in early 
Xenopus embryos.  Importantly, many findings originally discovered in Xenopus system have 
been subsequently validated in the mammalian systems [5, 6]. 
Myasthenia gravis (MG) is an acquired autoimmune disease of NMJ with a 
prevalence of 200-300 per million populations.  MG is heterogeneous in terms of 
pathophysiology, which is determined by the pathogenic autoantibodies (autoAbs) targeting 
to synaptic proteins at the NMJs [7•].  Approximately 85% of generalized MG patients have 
autoAbs against the acetylcholine receptors (AChRs) in the postsynaptic muscle membrane 
[8], and about 60% of the remaining patients have autoAbs against the muscle associated 
receptor tyrosine kinase (MuSK) and LDL receptor related protein 4 (LRP4) [9, 10].  In this 
review paper, we will describe our recently developed assay involving the use of Xenopus 
muscle or nerve-muscle cultures as an alternative CBA for MG diagnosis.  Afterwards, we 
will highlight the strengths of Xenopus tissue cultures as a research platform to elucidate the 
pathogenic mechanisms underlying AChR endocytosis in MG patients, and to develop 
potential therapeutic strategies by manipulating AChR endocytosis and degradation in MG 
pathogenesis. 
Development of functional NMJs in embryonic Xenopus nerve-muscle cultures 
The NMJ is comprised of the presynaptic motor nerve terminal, the postsynaptic 
muscle membrane, and the terminal Schwann cell [11].  The basal lamina components at 
synaptic cleft also contribute a crucial role in synaptic development.  The study of NMJ 
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development in tissue cultures is traceable back to the landmark discovery by Ross Harrison 
in 1907, in which he invented the “hanging drop” technique using the combined frog 
embryonic nerve fragments and lymphoid tissue to prepare explants on sterile coverslips [12]. 
This denotes the very first observation of nerve tissues that can be cultured, maintained, and 
grown outside the body.  Anderson et al. have further developed the preparation of nerve-
muscle co-cultures using dissociated tissues from early Xenopus embryos in the late 1970s 
[13].  They discovered that the formation of NMJs in vitro can be reproducibly observed 
when the dissociated Xenopus spinal neurons and muscle cells are cultured together, as 
evidenced by the accumulation of AChRs at nerve-muscle contact sites after the labeling with 
fluorescent α-bungarotoxin (α-BTX) (Figure 1b).  Moreover, by making successive 
observations on the same muscle cells, Anderson and Cohen demonstrated the re-distribution 
of fluorescently labeled AChRs upon synaptic induction [14].  Nerve-induced redistribution 
of AChRs is thus believed to be one of the initial steps in neuromuscular synaptogenesis.  
The development of functional NMJs after the initial establishment of a nerve-muscle contact 
was further supported by in vitro electrophysiological recordings on Xenopus nerve-muscle 
co-cultures [15] (Figure 1c).  Similar to the NMJs in mammalian systems, the developmental 
transition of AChR subunit composition from γ- to ε-subunit is also detected at Xenopus 
NMJs [16], reflecting the modulation of AChR channel properties during the 
developmentally regulated maturation of neuromuscular synapses in both mammalian and 
Xenopus systems. 
Regulation of AChR trafficking and clustering at developing NMJs 
The presence of a high density of AChR clusters at postsynaptic membrane is the 
most prominent feature of the NMJs.  Even prior to nerve innervation, AChRs are expressed 
and assembled in spontaneous clusters, called aneural AChR clusters, in Xenopus muscle 
cultures and other muscle cell lines [5, 17] (Figure 1b).  During neuromuscular 
synaptogenesis, it is widely believed that the induction, assembly, and maturation of AChR 
clusters at postsynaptic site are initiated by the stimulation of a nerve-derived heparan-sulfate 
proteoglycan agrin (AGRN) [18].  Binding of agrin to LRP4 activates MuSK that 
consequently causes AChR clustering through a cytoplasmic linker protein rapsyn, receptor 
associated protein of the synapse (RAPSN) [19-21].  In addition, agrin-induced MuSK 
activation causes dephosphorylation of aneural AChR clusters by tyrosine phosphatases, 
which eventually leads to the dispersal of aneural AChR clusters [22].  There are two non-
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mutually exclusive hypotheses that have been proposed to mediate redistribution of AChRs 
from extra-synaptic regions to the nascent postsynaptic sites for clustering.  First, the 
diffusion-trap mechanism suggests that nerve-induced assembly of cytoskeletal scaffolds may 
act as a trap to recruit and/or stabilize the mobile AChR molecules that exhibit random 
Brownian motion in the muscle membrane surface [23].  Second, AChRs at the aneural 
cluster may be internalized, transported via the endocytic vesicles, and then re-inserted to the 
synaptic sites by the vesicular trafficking mechanism.  The recycling of internalized AChRs 
is a calcium-dependent process, mediated by calcium-activated calmodulin-dependent kinase 
II (CaMKII) activity [24].  
Both actin and microtubule cytoskeleton are shown to be crucial for vesicular 
trafficking and clustering of AChRs at the postsynaptic sites [25, 26].  Agrin activates a small 
GTPase Cdc42 that in turn regulates Arp2/3 complex to promote actin polymerization 
through the activation of Wiskott Aldrich Syndrome protein (WASp) [27].  The postsynaptic 
stabilization of AChR clusters is achieved by the rapsyn-mediated linkage of the AChR to the 
cytoskeleton-anchored dystrophin-glycoprotein complex [28].  Apart from serving as a stable 
cytoskeletal scaffold for the docking and anchoring of structural and signaling molecules, our 
previous studies have provided definitive evidence to show that another dynamic pool of F-
actin, regulated by actin depolymerizing factor (ADF)/cofilin, actively facilitates the site-
directed delivery of AChRs to the nascent postsynaptic sites by modulating dynamic actin 
turnover locally.  ADF/cofilin may break the cortical actin barrier for allowing the fusion of 
AChR-containing vesicles with the plasma membrane [5].  As for the involvement of 
microtubules for AChR clustering, a recent study has demonstrated that an increase in 
microtubule capturing leads to an increase in AChR density at the postsynaptic membrane 
[29].  Agrin inhibits the phosphorylation of serine residues of microtubule plus end-tracking 
protein CLASP2.  Phosphatidylinositol-3,4,5-triphosphate (PIP3)-binding protein LL5β 
promotes the binding of CLASP2 to microtubule plus-ends in regulating microtubule 
capturing. 
Pathogenic mechanisms of AChR endocytosis and degradation in MG 
MG is a prototypical autoimmune neuromuscular disease caused by the attack of 
autoAbs against some crucial postsynaptic proteins at NMJs.  It has been shown from the 
clinical data that around 85% MG patients contain autoAbs against complex epitopes in 
different subunits of AChR, including cholinergic receptor nicotinic alpha 1 (CHRNA1), 
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cholinergic receptor nicotinic beta 1 (CHRNB1), cholinergic receptor nicotinic delta 
(CHRND), cholinergic receptor nicotinic epsilon (CHRNE), and cholinergic receptor 
nicotinic gamma (CHRNG) (Table 1), which represent the most typical type of autoAbs in 
seropositive MG (SPMG) patients [30].   The pathogenic mechanisms underlying SPMG are 
relatively well characterized, including antigenic modulation, activation of complement 
system, and inhibition of AChR channel function [7•, 31•] (Figure 2).  The antigenic 
modulation is initiated by the binding of autoAbs to antigens in AChR proteins, which 
induces receptor crosslinking and internalization, and eventually leads to the loss of surface 
AChRs from the postsynaptic membrane (Figure 2a).  The reduced number of postsynaptic 
AChRs decreases the amplitude of nerve-evoked end-plate potentials, and thereby the nerve 
signal is unlikely to initiate muscle contraction by depolarizing the muscle membrane 
potential beyond the threshold for generating an action potential.  In addition, the direct 
binding of autoAbs occupies the ligand-binding sites of AChRs, which prevents the 
activation of AChR from binding with ACh ligands released from the nerve terminal and 
leads to the inhibition of channel function (Figure 2b).  Regarding the activation of 
complement system, autoAbs against AChR belong to IgG1 subclass, consisting of bivalent 
Fc (fragment crystallizable region).  This suggests that binding of IgG1 to AChR activates the 
classical complement system.  Assembly of the membrane attack complex (MAC) triggers 
the influx of calcium ions that causes the destruction of postsynaptic membrane and 
junctional folds, as well as the lysis of muscle fibers (Figure 2c).  Taken together, antigenic 
modulation, complement activation, and channel inhibition are the major pathological 
mechanisms of MG. 
The remaining 15% MG patients that do not have anti-AChR autoAbs were initially 
considered as seronegative MG (SNMG) patients [30, 32, 33]; however, a considerable 
amount of work has been carried out to search for novel antigenic reactivity in SNMG 
patients in the past decades.  Now, more than half of the previously identified SNMG patients 
indeed pose autoAbs against MuSK.  Unlike MG caused by autoAbs against AChR (AChR-
MG), the pathogenic mechanism of autoAbs against MuSK (MuSK-MG) is not well 
understood.  It is believed that the pathogenic subclass of autoAbs involved in MuSK-MG 
belongs to IgG4 [34].  The presence of monovalent Fc due to Fab (fragment antigen-binding 
region) arm exchange making MuSK IgG4 follows a different immunological pathway to 
AChR depletion as in AChR-MG.  This evidence suggests that the depletion of AChR caused 
by anti-MuSK autoAbs is not complement-related.  It has been demonstrated that when the 
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passive transfer of the MG patient-derived IgG with high titres of MuSK antibody into mice, 
there is an internalization of MuSK followed by a reduction in the density and cluster size of 
AChRs at NMJs [32].  It is possible that the dimerization-induced MuSK activation by 
autoAbs leads to its depletion.  However, the exact pathogenic mechanism is yet to be 
revealed.  Apart from the autoAbs against MuSK, there is a growing list of autoAbs has been 
identified in those initially identified SNMG patients, which attack other synaptic proteins at 
the NMJs [7•], including AGRN, LRP4, RAPSN, collagen like tail subunit of asymmetric 
acetylcholinesterase (COLQ), cortactin (CTTN), potassium voltage-gated channel subfamily 
A member 4 (KCNA4), ryanodine receptor 1 (RYR1), and titin (TTN) (Table 1).  With the 
identification of these novel autoAbs, the percentage of SNMG has now been dramatically 
reduced.  Considering the high sequence homology of all these proteins between Xenopus 
and human (as summarized in Table 1), Xenopus tissue cultures offer an ideal assay for the 
study of autoAb-mediated pathogenic mechanisms underlying AChR endocytosis, 
trafficking, and degradation in MG pathogenesis. 
Xenopus cultures as an alternative cell-based assay for MG diagnosis 
In 1976, Lindstrom’s group firstly described a serological assay for MG diagnosis by 
detecting the presence of anti-AChR autoAbs with radioimmunoprecipitation assay (RIPA) 
[35].  In short, radioactive α-BTX molecules are added to bind with AChR proteins in human 
muscle extracts that serve as antigens for autoAbs.  After incubating the patient’s serum 
containing potential pathogenic autoAbs, co-precipitation is performed with the anti-human 
IgG antibodies.  Radioactivity of the pellets indicates the presence of anti-AChR autoAbs in 
the patient serum sample.  An alternative approach is enzyme-linked immunosorbent assay 
(ELISA), which was first adopted for MG diagnosis in 1984 [36].  In this assay, recombinant 
AChR proteins are coated on flat-bottom microtiter plate, followed by an incubation of 
patient serum samples.  Color given out by the reaction between peroxidase-conjugated anti-
human IgG and the substrate indicates the presence of autoAbs against AChR in the serum 
sample.  As the recombinant AChR proteins are in solution phase, some autoAbs against 
clustered AChR may not be detected in RIPA [37].  Besides, insufficient blocking may also 
give false positive results in ELISA. 
Despite RIPA and commercial ELISA kits have been widely adopted for MG 
diagnosis, their sensitivity is questionable.  A more sensitive approach using the cell-based 
assay (CBA) is therefore developed.  It has been shown that 66% of serum samples from 
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previously identified SNMG patients indeed contain low-affinity AChR-binding IgG against 
clustered AChR when CBA was used as the serological test [38••].  Co-expression of 
complementary DNA sequences encoding AChR and the anchoring protein, rapsyn, in human 
embryonic kidney (HEK) cells mimics the postsynaptic specializations of NMJ in vivo where 
AChRs are highly concentrated.  The presence of autoAbs in the patient serum sample is then 
determined by immunocytochemistry.  In comparison to RIPA and ELISA, CBA is 
considered as a more reliable approach for MG diagnosis [38••], which allows the expression 
of AChR proteins in a cellular environment to enable the localization and clustering of 
AChRs at a high density in anchorage to membrane surface via rapsyn.  This apparently 
improves the sensitivity of detecting the binding of low reactivity autoAbs against clustered 
AChRs.  
Apart from using heterologous cell lines, our recent study described the use of 
Xenopus tissue cultures as an alternative CBA for MG diagnosis and research [39••].  We 
were able to use Xenopus tissue cultures to detect the pathogenicity of serum samples from 
both SPMG and SNMG patients, as evidenced by a significant reduction of aneural and 
nerve-induced AChR clusters after incubating with MG patient serum samples (Figure 1b).  
The interaction between autoAbs in the serum samples from MG patients and proteins in the 
postsynaptic apparatus would cause the endocytosis and disassembly of aneural and nerve-
induced AChR clusters in pure muscle cultures and nerve-muscle co-cultures, respectively.  
Apart from the cell imaging approach to quantify the effects of MG serum on AChR cluster 
dispersal, Xenopus neuron-myoball co-cultures can also be employed to test the effects of 
MG patient serum samples on synaptic functions of NMJs by in vitro electrophysiological 
recordings (Figure 1c).  Spontaneous synaptic currents (SSCs) can be measured by the 
whole-cell patch-clamp recording method on 1-day-old neuron-myoball co-cultures before 
and after the incubation of MG patient serum samples.  The change in SSC frequency and/or 
amplitude implicates the effects of MG serum on presynaptic and/or postsynaptic inhibitions 
of neuromuscular functions, respectively.  Hence, the possibility of assessing the structural 
(cell imaging approach) and functional (electrophysiology approach) defects of NMJs after 
the treatment of pathogenic MG serum samples in Xenopus tissue cultures infers their 
potential to be used as an alternative CBA in MG diagnostic practice. 
One might argue on the feasibility of translating the knowledge obtained from the 
Xenopus model into our understanding of human diseases.  As shown in the recent 
completion of sequencing data, Xenopus genome shares a high level of spatial and functional 
9 
 
collinearity of genes with humans [40].  Xenopus is well positioned between distant 
invertebrates, like the fruit fly (Drosophila) and the worm (C. elegans), and the less 
accessible mammalian models [41].  Importantly, we have found that the amino acid 
sequence of some postsynaptic proteins in association to the MG pathogenesis shows a high 
degree of similarities between Xenopus and human (Table 1).  For instance, the amino acid 
sequences of AChR α1 subunit, CHRNA1, the ACh-binding subunit of AChR, in Xenopus 
tropicalis and Xenopus laevis share 74% and 73% similarity to that in human, respectively.  
Another important postsynaptic protein, MuSK, also shows more than 80% sequence 
homology between Xenopus species and human.  Taken together, this gives a strong 
argument that Xenopus tissue culture is an ideal platform for the serological diagnosis and the 
pathological research of MG. 
In search of therapeutic strategies for the treatment of MG using Xenopus tissue 
cultures 
Many potential strategies have been identified to alleviate the symptoms of muscle 
weakness after the onset of MG [7•].  One of the most commonly used medications is the 
reversible acetylcholinesterase (AChE) inhibitor, pyridostigmine [42].  The increased level 
and duration of neurotransmitter acetylcholine by inhibiting AChE activity at the synaptic 
cleft can alleviate muscle weakness in MG patients.  However, the transient and mild effects 
of AChE inhibition are insufficient to treat MG [43], and may also contribute to various side 
effects, such as muscarinic overactivity, nicotinic side effects, and cholinergic crisis state 
[44].  Other common treatments to MG also include the immunosuppressant drug, the 
plasmapheresis, the immunoglobulin therapy, and thymectomy [7•].  These treatment 
strategies, however, cannot give a complete remission for MG patients, which urge the 
development of advanced therapeutic approaches for MG treatment in the future. 
At mature NMJs, it has long been believed that AChRs are metabolically stable in the 
postsynaptic membrane at the mature NMJs, until they are internalized and targeted to 
lysosomes for protein degradation [45].  In fact, some internalized AChRs are recycled and 
inserted back to the postsynaptic membrane for maintaining a high postsynaptic AChR 
density [24, 46].  Using biotin-α-BTX and streptavidin-conjugates of different fluorophores, 
it is possible to distinguish various pools of AChRs, namely pre-existing, recycling, and 
newly synthesized AChRs [46, 47].  This sequential labeling approach will allow us to 
investigate the trafficking mechanisms of endocytosed AChR vesicles following endocytosis.  
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Our long-term goal is to develop a potential therapeutic strategy that alleviates the loss of 
AChRs at NMJs in MG pathogenesis.  One of the possible therapeutic approaches is to 
manipulate the trafficking and stability of synaptic AChR clusters.  Given the fact that the 
loss of AChR clusters is triggered by autoAb-induced crosslinking followed by endocytosis 
of AChRs, a therapeutic strategy can be developed to modulate the rate of AChR endocytosis 
and/or to regulate the recycling of endocytosed AChRs, so as to maintain the high density of 
AChR clusters for efficient neurotransmission between motor neurons and muscle fibers.  
Our recent studies using Xenopus muscle cells have demonstrated the spatial and temporal 
correlation between ADF/cofilin localization and the clustering of AChRs at developing 
NMJs [5].  We also observed the disassembly of AChR clusters and the disappearance of 
ADF/cofilin localization upon the treatment of MG patient serum samples, suggesting that 
pathogenic autoAbs regulate ADF/cofilin localization and function for the dispersal of AChR 
clusters [39••].  It is of interest to further investigate if manipulating the activity of 
ADF/cofilin or its upstream regulators could inhibit the endocytosis and degradation of 
AChR clusters in response to MG serum treatment.   
Our recent study reported a procedure to mimic the pathogenic autoAbs for inducing 
the crosslinking and endocytosis of AChRs in Xenopus tissue cultures [48•].  In that study, 
we took advantage of the multivalent interaction between biotin and streptavidin to crosslink 
the biotin-α-BTX-labeled AChR molecules by streptavidin-quantum dots (QDs) (Figure 2d).  
QDs are nanometer-sized semiconductor particles that are much brighter and more stable 
than traditional organic fluorescent probes, which allow us to visualize and perform long-
term tracking of internalized AChR vesicles upon receptor crosslinking-induced AChR 
endocytosis.  The unique features of QDs, which include the direct relationship between the 
QD-emitted wavelength of fluorescence emission and its size, the multicolor imaging from 
wide excitation and narrow emission range, and the possible detection of QDs in transmission 
electron microscopy (TEM) without chemical staining [49], offer a powerful tool for single-
molecule imaging and tracking.  By using correlative light and electron microscopy (CLEM) 
[50], high resolution correlative microscopy images can be acquired to characterize the 
particular subcellular structures in association with the endocytic trafficking and lysosomal 
degradation pathways of endocytosed AChRs upon the crosslinking action by streptavidin-
QDs.  Therefore, QDs can be employed not only to visualize and track the surface movement 
of AChRs during the formation of synaptic AChR clusters in live muscle cells [51], but also 
the multivalent interaction between biotin and streptavidin allows us to track the internalized 
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AChR vesicles following the crosslinking-induced endocytosis [48•].  As this crosslinking 
effect mimics the antigenic modulation, one of the pathogenic mechanisms of autoAbs that 
induces internalization of crosslinked AChR clusters in MG patients, a possible treatment 
may be developed to interfere the clathrin-mediated endocytic pathway, which has been 
implicated to regulate the crosslinking-induced AChR endocytosis in cultured muscle cells 
[48•].  Therefore, the reduced level of antigenic modulation should prevent the loss of AChR 
clusters in postsynaptic membrane.  Taken together, Xenopus tissue cultures offer a simple in 
vitro assay to study and manipulate the pathogenic mechanisms in MG.   
 Conclusion 
In light of the potential pitfalls of all current diagnostic assays described above, it is 
essential to develop a more reliable, sensitive, and specific tool for the diagnosis of MG, even 
at the early stage of pathogenesis.  Although most CBAs are relatively labor intensive, 
Xenopus tissue culture-based serological test is a promising tool for the initial clinical 
diagnosis of MG by testing autoAb pathogenicity in vitro.  This assay can also be employed 
to distinguish the disease severity among different patients, and to monitor the course of the 
disease and the efficacy of treatment received for a particular MG patient.  Additionally, 
Xenopus tissue cultures provide an important research platform for elucidating the pathogenic 
mechanisms underlying AChR endocytosis in both seropositive and seronegative MG 
patients.  Therefore, results of these studies using Xenopus tissue cultures should contribute 
to a better understanding of the etiology of MG and provide a therapeutic intervention for this 
malady in the future. 
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Figures 
 
  
Figure 1.  Experimental approaches to examine the effects of autoantibodies in MG patient 
serum on the synaptic structure and function of NMJs in vitro.  (a) The dorsal part (dotted lines, 
highlighted regions in green) of a 1-day-old Xenopus embryo (at stage 22), which contains neural tube 
(NT), somite (S), and notochord (NC), is dissected and then subjected to enzymatic collagenase 
treatment.  Somite tissues are dissociated and plated separately to prepare muscle cultures, or together 
with neural tube tissues to prepare neuron-muscle co-cultures.  (b) Left: Spontaneously formed 
aneural AChR clusters (inset) are observed by live labeling the muscle cells with rhodamine-
conjugated α-bungarotoxin (red).  Right: In neuron-muscle co-cultures, nerve-induced AChR clusters 
(inset, arrows) are found to be spatially localized along the contact sites between neurons and muscle 
cells (dotted lines).  Arrowhead points to the cell body of a spinal neuron.  (c) Dissociated muscle 
cells (M) and spinal neurons (N) are plated on plain glass coverslips for electrophysiological 
recordings.  Spontaneous synaptic currents (SSCs) are recorded from the innervated muscle cells in 1-
day-old neuron-myoball co-cultures by the whole-cell patch clamp technique.  The effects of MG 
patient serum samples on the synaptic structure and function of NMJs can be examined by cellular 
imaging and electrophysiology approaches, respectively.  Scale bars represent 20 μm. 
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Figure 2.  The pathological mechanisms of anti-AChR autoAbs and the experimental approach 
to mimic the pathogenic autoAbs for inducing the crosslinking and internalization of AChRs in 
MG.  Pathological mechanisms: (a) Antigenic modulation: The binding of autoAbs to AChRs causes 
crosslinking and internalization of AChRs.  Then, the endocytosed AChRs are targeted to lysosomal 
degradation, leading to the loss of AChR density at the end plates of NMJs.  (b) Channel inhibition: 
The binding of autoAbs to the ligand-binding site of AChRs directly inhibits the function of AChR 
channels in mediating membrane depolarization.  (c) Complement activation: The binding of autoAbs 
to AChR leads to the assembly of C1 complement complex and membrane attack complex (MAC), 
which consequently causes the destruction of junctional fold structures in the sarcolemma and the cell 
lysis through the calcium influx via MAC.  Experimental approach: (d) Tracking of endocytosis 
AChRs by QDs: To mimic the crosslinking-induced endocytosis mediated by autoAbs, AChRs are 
first labeled with biotin-conjugated α-bungarotoxin (biotin-BTX), followed by the addition of 
streptavidin-conjugated quantum dot (streptavidin-QD).  Due to the multivalent interaction between 
biotin and streptavidin, QD allows us to visualize and perform long-term tracking of AChR vesicles 
upon receptor crosslinking-induced endocytosis in live cells.  
14 
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